Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Weight Gain, Eating Patterns, and Development of Body Composition During Initiation of Basal Insulin Therapy in Patients With Type 2 Diabetes: A Comparison of Insulin Detemir [Levemir] and Insulin Glargine [Lantus].

Trial Profile

Weight Gain, Eating Patterns, and Development of Body Composition During Initiation of Basal Insulin Therapy in Patients With Type 2 Diabetes: A Comparison of Insulin Detemir [Levemir] and Insulin Glargine [Lantus].

Discontinued
Phase of Trial: Phase III

Latest Information Update: 23 May 2013

At a glance

  • Drugs Insulin detemir (Primary) ; Insulin glargine (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 31 Oct 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 20 Jan 2011 Planned end date changed from 1 Nov 2010 to 1 Oct 2010 as reported by ClinicalTrials.gov.
    • 29 Jan 2010 Planned end date changed from 1 Oct 2009 to 1 Nov 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top